Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy

por Leder, Benjamin Z
Publicado 2018

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis

por Leder, Benjamin Z, Mitlak, Bruce, Hu, Ming-yi, Hattersley, Gary, Bockman, Richard S
Publicado 2019

The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA‐HD Study Extension

por Ramchand, Sabashini K., David, Natalie L., Lee, Hang, Bruce, Michael, Bouxsein, Mary L., Tsai, Joy N., Leder, Benjamin Z.
Publicado 2022

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

por Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Publicado 2019

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis

por Dempster, David W, Zhou, Hua, Rao, Sudhaker D, Recknor, Chris, Miller, Paul D, Leder, Benjamin Z, Annett, Miriam, Ominsky, Michael S, Mitlak, Bruce H
Publicado 2021

Romosozumab and antiresorptive treatment: the importance of treatment sequence

por Cosman, Felicia, Kendler, David L., Langdahl, Bente L., Leder, Benjamin Z., Lewiecki, E. Michael, Miyauchi, Akimitsu, Rojeski, Maria, McDermott, Michele, Oates, Mary K., Milmont, Cassandra E., Libanati, Cesar, Ferrari, Serge
Publicado 2022